nicorandil has been researched along with Elevated Cholesterol in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Genda, S; Ichikawa, Y; Miki, T; Miura, T; Shimamoto, K | 1 |
| Ambrosi, P; Andréjak, M; Gayet, JL | 1 |
1 review(s) available for nicorandil and Elevated Cholesterol
| Article | Year |
|---|---|
[The best of clinical pharmacology in 2002].
Topics: Anticholesteremic Agents; Antihypertensive Agents; Azetidines; Cardiovascular Diseases; Ezetimibe; Hormone Replacement Therapy; Humans; Hydrazones; Hypercholesterolemia; Losartan; Myocardial Infarction; Natriuretic Agents; Natriuretic Peptide, Brain; Neovascularization, Physiologic; Nicorandil; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Vasodilator Agents | 2003 |
1 other study(ies) available for nicorandil and Elevated Cholesterol
| Article | Year |
|---|---|
K(ATP) channel opening is an endogenous mechanism of protection against the no-reflow phenomenon but its function is compromised by hypercholesterolemia.
Topics: Adenosine Triphosphate; Analysis of Variance; Animals; Chronic Disease; Coronary Circulation; Disease Models, Animal; Glyburide; Hemodynamics; Hypercholesterolemia; Male; Myocardial Infarction; Nicorandil; Nitric Oxide Synthase; omega-N-Methylarginine; Potassium Channel Blockers; Potassium Channels; Rabbits; Vasodilator Agents | 2002 |